Alnylam Pharmaceuticals and Paradigm4 partnered to uncover genetic and metabolic drivers of disease based on UK BioBank's unprecedented data set (1.5PB+ of multi-modal, longitudinal data shared by 500,000 UK citizens, including genomic, clinical, self-reported, behavioral, imaging and biometric information). Paradigm4’s scientific computing platform streamlined creation of custom phenotypes across all data modalities, provided rapid access to precise cohorts, and ran computationally intensive genome/phenome association algorithms (GWAS)—with 1 billion linear regressions in an hour—using thousands of spot CPU cores at the push of a button. The collaboration enabled Alnylam to establish a human genetics program in less than a year, publish multiple significant results, and optimize cloud cost/performance.
Presented by Alex Poliakov, V.P. Customer Solutions, Paradigm4
and Greg Hinkle,V.P Research Informatics, Alnylam Pharmaceuticals
